Federico Iacovelli

Dr. Federico Iacovelli

Università di Roma Tor Vergata
orcid

Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
10 September 2019 in Nutrients
Verified
Journal Article
Open access
PDF file
LVLaura Vollono
Laura Vollono
Mattia FalconiMattia Falconi
Mattia Falconi
Roberta GazianoRoberta Gaziano
Roberta Gaziano
Federico IacovelliFederico Iacovelli
Federico Iacovelli
Emi DikaEmi Dika
Emi Dika
Elena CampioneElena Campione
Elena Campione
Curcumin is a compound isolated from turmeric, a plant known for its medicinal use. Recently, there is a growing interest in the medical community in identifying novel, low-cost, safe molecules that may be used in the treatment of inflammatory and neoplastic diseases. An increasing amount of evidence suggests that curcumin may represent an effective agent in the treatment of several skin conditions. We examined the most relevant in vitro and in vivo studies published to date regarding the use of curcumin in inflammatory, neoplastic, and infectious skin diseases, providing information on its bioavailability and safety profile. Moreover, we performed a computational analysis about curcumin’s interaction towards the major enzymatic targets identified in the literature. Our results suggest that curcumin may represent a low-cost, well-tolerated, effective agent in the treatment of skin diseases. However, bypass of limitations of its in vivo use (low oral bioavailability, metabolism) is essential in order to conduct larger clinical trials that could confirm these observations. The possible use of curcumin in combination with traditional drugs and the formulations of novel delivery systems represent a very promising field for future applicative research.

29 October 2013 in ACS Nano
Verified
Journal Article
Closed access
SJSissel Juul
Sissel Juul
Federico IacovelliFederico Iacovelli
Federico Iacovelli
Mattia FalconiMattia Falconi
Mattia Falconi
SKSofie L. Kragh
Sofie L. Kragh
BCBrian Christensen
Brian Christensen
BKBirgitta Knudsen
Birgitta Knudsen

21 August 2019 in Communications Biology
Verified
Journal Article
Open access
PDF file
KAKATIA AQUILANO
KATIA AQUILANO
VCVeronica Ceci
Veronica Ceci
AGAngelo Gismondi
Angelo Gismondi
SSSusanna De Stefano
Susanna De Stefano
Federico IacovelliFederico Iacovelli
Federico Iacovelli
Daniele Lettieri-BarbatoDaniele Lettieri-Barbato
Daniele Lettieri-Barbato
There is a growing interest in therapeutically targeting the inflammatory response that underlies age-related chronic diseases including obesity and type 2 diabetes. Through integrative small RNA sequencing, we show the presence of conserved plant miR159a and miR156c in dried nuts having high complementarity with the mammalian TNF receptor superfamily member 1a (Tnfrsf1a) transcript. We detected both miR159a and miR156c in exosome-like nut nanovesicles (NVs) and demonstrated that such NVs reduce Tnfrsf1a protein and dampen TNF-α signaling pathway in adipocytes. Synthetic single-stranded microRNAs (ss-miRs) modified with 2′-O-methyl group function as miR mimics. In plants, this modification naturally occurs on nearly all small RNAs. 2′-O-methylated ss-miR mimics for miR156c and miR159a decreased Tnfrsf1a protein and inflammatory markers in hypertrophic as well as TNF-α-treated adipocytes and macrophages. miR156c and miR159a mimics effectively suppress inflammation in mice, highlighting a potential role of plant miR-based, single-stranded oligonucleotides in treating inflammatory-associated metabolic diseases.

23 January 2020 in Cell Death & Disease
Verified
Journal Article
Open access
PDF file
RTRiccardo Turchi
Riccardo Turchi
FTFlavia Tortolici
Flavia Tortolici
GGGiulio Guidobaldi
Giulio Guidobaldi
Federico IacovelliFederico Iacovelli
Federico Iacovelli
MFMattia Falconi
Mattia Falconi
KAKATIA AQUILANO
KATIA AQUILANO
Decreased expression of mitochondrial frataxin (FXN) causes Friedreich’s ataxia (FRDA), a neurodegenerative disease with type 2 diabetes (T2D) as severe comorbidity. Brown adipose tissue (BAT) is a mitochondria-enriched and anti-diabetic tissue that turns excess energy into heat to maintain metabolic homeostasis. Here we report that the FXN knock-in/knock-out (KIKO) mouse shows hyperlipidemia, reduced energy expenditure and insulin sensitivity, and elevated plasma leptin, recapitulating T2D-like signatures. FXN deficiency leads to disrupted mitochondrial ultrastructure and oxygen consumption as well as lipid accumulation in BAT. Transcriptomic data highlights cold intolerance in association with iron-mediated cell death (ferroptosis). Impaired PKA-mediated lipolysis and expression of genes controlling mitochondrial metabolism, lipid catabolism and adipogenesis were observed in BAT of KIKO mice as well as in FXN-deficient T37i brown and primary adipocytes. Significant susceptibility to ferroptosis was observed in adipocyte precursors that showed increased lipid peroxidation and decreased glutathione peroxidase 4. Collectively our data point to BAT dysfunction in FRDA and suggest BAT as promising therapeutic target to overcome T2D in FRDA.

1 June 2018 in Nanomedicine: Nanotechnology, Biology and Medicine
Verified
Journal Article
Open access
SRSofia Raniolo
Sofia Raniolo
GVGiulia Vindigni
Giulia Vindigni
AOAlessio Ottaviani
Alessio Ottaviani
VUValeria Unida
Valeria Unida
Federico IacovelliFederico Iacovelli
Federico Iacovelli
SBSilvia Biocca
Silvia Biocca
Selective targeting is a crucial property of nanocarriers used for drug delivery in cancer therapy. We generated biotinylated octahedral DNA nanocages functionalized with folic acid through bio-orthogonal conjugation chemistry. Molecular modelling indicated that a distance of about 2.5 nm between folic acid and DNA nanocage avoids steric hindrance with the folate receptor. HeLa cells, a folate receptor positive tumour cell line, internalize folate-DNA nanocages with efficiency greater than 40 times compared to cells not expressing the folate receptors. Functionalized DNA nanocages are highly stable, not cytotoxic and can be efficiently loaded with the chemotherapeutic agent doxorubicin. After entry into cells, doxorubicin-loaded nanoparticles are confined in vesicular structures, indicating that DNA nanocages traffic through the endocytic pathway. Doxorubicin release from loaded DNA cages, facilitated by low pH of endocytic vesicles, induces toxic pathways that, besides selectively killing folate receptor-positive cancer cells, leads to cage degradation avoiding nanoparticles accumulation inside cells.

Elena CampioneElena Campione
Elena Campione
CLCaterina Lanna
Caterina Lanna
Terenzio CosioTerenzio Cosio
Terenzio Cosio
Luigi RosaLuigi Rosa
Luigi Rosa
MCMaria Pia Conte
Maria Pia Conte
LBLuca Bianchi
Luca Bianchi
Lactoferrin (Lf), a multifunctional cationic glycoprotein synthesized by exocrine glands and neutrophils, possesses an in vitro antiviral activity against SARS-CoV-2. Thus, we conducted an in vivo preliminary study to investigate the antiviral effect of oral and intranasal liposomal bovine Lf (bLf) in asymptomatic and mild-to-moderate COVID-19 patients. From April 2020 to June 2020, a total of 92 mild-to-moderate (67/92) and asymptomatic (25/92) COVID-19 patients were recruited and divided into three groups. Thirty-two patients (14 hospitalized and 18 in home-based isolation) received only oral and intranasal liposomal bLf; 32 hospitalized patients were treated only with standard of care (SOC) treatment; and 28, in home-based isolation, did not take any medication. Furthermore, 32 COVID-19 negative, untreated, healthy subjects were added for ancillary analysis. Liposomal bLf-treated COVID-19 patients obtained an earlier and significant (p < 0.0001) SARS-CoV-2 RNA negative conversion compared to the SOC-treated and untreated COVID-19 patients (14.25 vs. 27.13 vs. 32.61 days, respectively). Liposomal bLf-treated COVID-19 patients showed fast clinical symptoms recovery compared to the SOC-treated COVID-19 patients. In bLf-treated patients, a significant decrease in serum ferritin, IL-6, and D-dimers levels was observed. No adverse events were reported. These observations led us to speculate a potential role of bLf in the management of mild-to-moderate and asymptomatic COVID-19 patients.